Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxinN-methyl-4-phenylpyridinium (MMP+) towards cultured dopaminergic neuroblastoma cells
- 1 October 1995
- journal article
- Published by Springer Nature in Psychopharmacology
- Vol. 121 (3) , 373-378
- https://doi.org/10.1007/bf02246077
Abstract
Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+). This conversion of haloperidol to HP+ appears to be similar to the activation of the dopaminergic neurotoxinN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toN-methyl-4-phenyl pyridinium ion (MPP+). MPP+ is responsible for the damage of striatal dopaminergic neurons induced by MPTP in humans and animals. It seemed sensible to investigate whether or not HP+ might be toxic towards dopaminergic neurons and perhaps associated with some of the residual motofunction side effects of haloperidol. We therefore investigated the neurotoxicity of HP+ toward cultured human dopamine neuroblastoma cells (SH-SY5Y) and compared it with that of MPP+. HP+ reduced the viability as measured by MTT and [3H]thymidine incorporation methods in SH-SY5Y cells. Cell membrane integrity is reduced by the treatment of HP+ as measured by intracellular LDH levels. The toxicity was concentration and time dependent. Interestingly, HP+ appeared to be more toxic than MPP+ towards the SH-SY5Y cells in early phase in cultures. The toxicity of MPP+ appear to be progressive and subsequently become more than HP+ with prolonged cultivation. In contrary to MPP+, the toxic effect of HP+ towards a dopamine transporter transfected SK-N-MC cell line is not different from its wild type. This indicates that dopamine uptake system is probably not involved in the cytotoxicity caused by HP+.Keywords
This publication has 25 references indexed in Scilit:
- Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated ratsPharmacology Biochemistry and Behavior, 1993
- High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparationsJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometryInternational Journal of Mass Spectrometry and Ion Processes, 1992
- Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neuronsBiochemical and Biophysical Research Communications, 1991
- Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metaboliteToxicology Letters, 1991
- One year treatment with haloperidol or clozapine fails to alter neostriatal D1- and D2-dopamine receptor sensitivity in the ratBrain Research, 1989
- 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptomsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- MPTP Toxicity: Implications for Research in Parkinson's DiseaseAnnual Review of Neuroscience, 1988
- Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.Proceedings of the National Academy of Sciences, 1985